Platform Component Articles & Analysis
9 news found
About Orgenesis Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare ...
“As solutions provider and platform integrator, Gerresheimer has deep development and manufacturing know-how as well as a strong network of global pharma and biotech customers. ...
Johnson & Johnson MedTech* announced today that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S. to evaluate the safety and effectiveness of ...
Protease inhibitor is a key component of Oramed’s PODTM technology that protects therapeutic proteins in the digestive system Oramed has already been granted this patent in the United States and Japan Oramed Pharmaceuticals Inc. ...
If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://conference.snn.network/agenda News Compliments of Accesswire About Orgenesis Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an ...
Gières (Grenoble), France, January 19, 2021 - eCential Robotics, a French growth company that designs and produces the only system fully unifying 2D/3D robotic imaging and surgical navigation, and previously known as Surgivisio, today announced the rebranding of its identity. The rebranding contributes to the strengthening of the Grenoble-based company's position as a rising player in ...
Additionally, the platform increases the safety of pharmaceuticals by evaluating the mechanisms of toxicity as they may differ from individual-to-individual. This novel platform has the potential to become an essential tool in personalizing the prescription of drug types and doses for specific therapeutics. ...
“I am pleased to announce that after years of development and refinement, VisionGate’s proprietary, breakthrough technology, the Cell-CT platform, is poised to be a key component in the cancer continuum of care”, said Alan C. ...
All things - when combined - form a hugely versatile platform suitable for a great range of tasks, and the modularity of the ship configuration enables changes in short time and facilitates future upgrades. ...